Home > News > Octoplus and Cytimmune give anticancer drug TNF new chance
May 28th, 2003
Octoplus and Cytimmune give anticancer drug TNF new chance
Abstract:
OctoPlus and CytImmune Sciences, Inc., announced today that they have entered into a collaboration agreement to develop a novel treatment for solid cancers. The treatment's active agent is the anticancer protein, tumor necrosis factor (TNF). (see 2nd story)
Source:
Octoplus
Bookmark:
| Related News Press |
Nanomedicine
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
SMART researchers pioneer first-of-its-kind nanosensor for real-time iron detection in plants February 28th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||